Biotech

All Articles

Zenas, MBX, Bicara scalp to Nasdaq in very hot time for biotech IPOs

.It is actually an unusually active Friday for biotech IPOs, with Zenas BioPharma, MBX as well as Bi...

Atea's COVID antiviral falls short to stop hospitalizations in period 3

.Atea Pharmaceuticals' antiviral has neglected one more COVID-19 test, but the biotech still keeps o...

Neurocrine's offer to spare mental illness possibility falls short

.Neurocrine Biosciences' mental illness system pivot has actually neglected. The biotech was actuall...

Sanofi pays for $110M upfront for late-stage radioligand therapy

.Sanofi has actually created a late access to the radioligand celebration, paying 100 million europe...

F 2G rears $100M for second try to receive brand new antifungal to market

.After F2G's initial attempt to obtain a new training class of antifungal to market was actually thw...

Moderna targets $1.1 B in R&ampD costs cuts, falls 5 courses amidst profitability pressures

.Moderna has actually pledged to reduce R&ampD spending by $1.1 billion by 2027. The selection to re...

Sanofi's $80M bank on Pivot dystrophy drug finishes in period 3 go bust

.Merely four months after Sanofi wager $80 million in beforehand cash money on Fulcrum Therapies' lo...

Oncternal share drains 60% amid discharges, trial firings

.Cancer provider Oncternal Therapies is folding all its own clinical trials and giving up team, tran...

Roche is supporting out hopes that its own injectable excessive weight possibility could inevitably illustrate 25% weight reduction in late-stage trial

.Roche is actually keeping out chances that its injectable being overweight possibility could at som...

Novo Nordisk barrages 'remarkable' fat loss lead for dual-acting dental medication in very early test

.Novo Nordisk has lifted the cover on a stage 1 trial of its own dental amylin and GLP-1 receptor co...